Palopegteriparatide
FDA-approved once-daily PTH (parathyroid hormone, which manages calcium) prodrug for hypoparathyroidism (Yorvipath).
What it's for
FDA-approved once-daily PTH (parathyroid hormone, which manages calcium) prodrug for hypoparathyroidism (Yorvipath).
What it's for
Palopegteriparatide is a PEGylated prodrug that releases PTH (parathyroid hormone, which manages calcium) continuously to replace missing parathyroid hormone action. It treats hypoparathyroidism in adults, aiming to control serum calcium and reduce large supplemental calcium/active vitamin D needs.
What it does for the body
It treats hypoparathyroidism in adults, aiming to control serum calcium and reduce large supplemental calcium/active vitamin D needs. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Steady PTH1 receptors (lock-and-key landing spots on cells) stimulation restores renal calcium reabsorption and phosphate handling more physiologically than high-dose calcium alone. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Palopegteriparatide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Palopegteriparatide — FDA.gov search
- ClinicalTrials.gov search: Palopegteriparatide — U.S. clinical trials registry
- Drugs@FDA search: Palopegteriparatide — FDA drug database (if approved)
- PubMed search: Palopegteriparatide — NCBI PubMed
- PubMed Central search: Palopegteriparatide — NCBI PMC